ViroCell said MHRA’s manufacturing approval will allow it to produce viral vectors at Great Ormond Street Hospital (GOSH) for CGT clinical trials.

Contract development manufacturing organization (CDMO) ViroCell Biologics said the viral vector manufacturing license granted by the Medicines and Healthcare products Regulatory Agency (MHRA) enables it to produce and globally distribute viral vectors for cell and gene therapy (CGT) clinical trial use from GOSH’s London facility, named the Zayed Center for Research.

Click the link in the title to read more

News from Disruptive capital GP Limited